Advertisement
U.S. markets closed
Advertisement

Amarin Corporation plc (AMRN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
0.7500-0.0320 (-4.09%)
At close: 04:00PM EST
0.7551 +0.01 (+0.68%)
After hours: 07:39PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
Previous Close0.7820
Open0.7603
Bid0.7550 x 3200
Ask0.7598 x 1200
Day's Range0.7400 - 0.7795
52 Week Range0.6500 - 2.2300
Volume1,657,859
Avg. Volume1,547,909
Market Cap306.219M
Beta (5Y Monthly)2.11
PE Ratio (TTM)N/A
EPS (TTM)-0.1200
Earnings DateFeb 14, 2024 - Feb 19, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.05
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for AMRN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Amarin Corporation plc
    Analyst Report: AbbVie Inc.AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more